# Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

> **NCT07184424** · NA · COMPLETED · sponsor: **Beijing Tsinghua Chang Gung Hospital** · enrollment: 24 (actual)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT07184424
- **Lead sponsor:** Beijing Tsinghua Chang Gung Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-24
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184424, "Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07184424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*